Ascendia Pharmaceuticals Announces Issuance of New Patent for Acute Coronary Syndrome ProgramAscendia Pharmaceuticals Announces Issuance of New Patent for Acute Coronary Syndrome Program
Ascendia Pharmaceuticals, a specialty pharmaceutical company engaged in nano-formulation design, development, and manufacture for poorly soluble molecules, recently announced it has been awarded a new patent.

Pfizer CentreOne Expands Fill-Finish Services Pfizer CentreOne Expands Fill-Finish Services
Pfizer CentreOne, a global contract manufacturing organization embedded within Pfizer, recently announced that it has expanded its fill-finish services to its Kalamazoo, MI, site.

Metrics Contract Services: Your "Concept to Commercialization" PartnerMetrics Contract Services: Your "Concept to Commercialization" Partner
The parent company of Metrics Contract Services, Mayne Pharma, is investing $80 million to significantly expand facilities and equipment at its site in Greenville, N.C.

Foster Delivery Science & ProMed Pharma Partner Foster Delivery Science & ProMed Pharma Partner
Foster Delivery Science and ProMed Pharma have entered into a commercial partnership to provide comprehensive contract services for pharmaceutical and combination device applications.

Pharma & Biotech: 2017 Review of Outsourced ManufacturingPharma & Biotech: 2017 Review of Outsourced Manufacturing
Based on our analysis, the outsourced manufacturing sector is a fertile ground for investment, based on the growth prospects above expected GDP growth and the sub-sectors that can excel in the sector. Industry M&A trends over the last decade have transformed the outsourced manufacturing sector with some significant players emerging.

Next-Generation Silicone Adhesive Technologies Key to Broader Global Adoption, Growth of Wearable Medical DevicesNext-Generation Silicone Adhesive Technologies Key to Broader Global Adoption, Growth of Wearable Medical Devices
Dow Corning, a global leader in silicones, silicon-based technology, and innovation and a wholly owned subsidiary of The Dow Chemical Company, sees the role of specialized adhesive technologies as a key driver of this growth – especially in skin-adhered medical devices, a major segment of the wearables market.

SiO2 Medical Products, Inc. Receives Marketing Authorization for Filled 6-mL Vials SiO2 Medical Products, Inc. Receives Marketing Authorization for Filled 6-mL Vials
SiO 2 Medical Products, Inc. (SMP) received marketing authorization (MA) for the Type II variation of the primary packaging of zoledronic acid from the German Medicines Authority BfArM on November 25, 2016. The drug, zoledronic acid, is packaged in a proprietary 6-mL vial developed by SMP.

Patheon Announces Completion of its Acquisition of State-of-the-Art Manufacturing SitePatheon Announces Completion of its Acquisition of State-of-the-Art Manufacturing Site
Patheon N.V, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced that it has completed the acquisition of a state-of-the-art manufacturing facility in Florence, SC, from Roche Holdings, Inc. Patheon has begun integrating the site into the Patheon network.

West Introduces LyoSeal® Instant Sealing Solution & NovaGuard® SA Pro Safety System West Introduces LyoSeal® Instant Sealing Solution & NovaGuard® SA Pro Safety System
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, recently introduced two new offerings at Pharmapack Europe 2017.

Ompi Presents its Integrated Needlestick Protection Ompi Presents its Integrated Needlestick Protection
Ompi expands its Ompi EZ-fill® Syringes offer by adding up an Integrated Safety System (ISS) for staked needle syringes. Ompi EZ-fill® ISS is a brand new fully passive safety system designed to guarantee end users’ safety and reduce total cost of ownership for the pharmaceutical companies.

Terumo & Nemera Announce Validated Compatibility Between PLAJEX Polymer Prefillable Syringes & Safe'n'Sound Terumo & Nemera Announce Validated Compatibility Between PLAJEX Polymer Prefillable Syringes & Safe'n'Sound
To serve the needs of the pharmaceutical industry and users, Nemera and Terumo agreed to cooperate to confirm compatibility between PLAJEXTM COP prefillable syringes and the Safe’n’Sound® platform, an add-on passive sharps injury protection device for prefilled syringes (PFS).

Mikron Automation Expands US Headquarters in Metro DenverMikron Automation Expands US Headquarters in Metro Denver
Mikron Automation and Denver-based Confluent Development are pleased to announce the expansion of Mikron Automation’s U.S. headquarters in Arapahoe County’s Dove Valley Business Park.

Antibacterial Drugs Market Will Hit $35.6 Billion by 2022Antibacterial Drugs Market Will Hit $35.6 Billion by 2022
The antibacterial drugs market is set to grow from $27.7 billion in 2015 to $35.6 billion by 2022, representing a compound annual growth rate of 3.97%, according to business intelligence provider GBI Research.

Elemental Impurities: Implications for Manufacturers of Drug Products, APIs & ExcipientsElemental Impurities: Implications for Manufacturers of Drug Products, APIs & Excipients
The International Conference on Harmonization (ICH) finalized the ICH Q3D Guideline for elemental impurities in December 2014. 1 Regulators are now implementing the requirements worldwide, with some start dates already in place as of June 2016.

Avomeen Recapitalizes to Achieve Next Growth Plan Objective Avomeen Recapitalizes to Achieve Next Growth Plan Objective
In an effort to foster growth and reinforce its infrastructure, Avomeen Analytical Services, a fast growing full-service independent analytical and chemical testing laboratory based in Ann Arbor, MI, recently announced a recapitalization with High Street Capital, a Chicago-based provider of flexible capital and operating expertise to middle market businesses.

Gerresheimer Introduces Metal-Free Syringe Gerresheimer Introduces Metal-Free Syringe
Biopharmaceuticals demonstrate a series of special features. They are often highly viscous and in individual cases tend to interact with silicone oil or, for example, tungsten residue from syringe production..........

PCI Clinical Services & Suvoda Announce Strategic PartnershipPCI Clinical Services & Suvoda Announce Strategic Partnership
PCI Clinical Services recently announced a partnership with Suvoda LLC that will benefit clinical trials, delivering Suvoda’s cutting-edge IRT/IWRS technology for subject randomization and trial supply management integrated with PCI’s comprehensive packaging and logistical services for clinical trial supplies.

Nemus Bioscience Announces Licensing Agreement for a Cannabinoid-Based Anti-Infective Platform Directed Against Drug-Resistant OrganismsNemus Bioscience Announces Licensing Agreement for a Cannabinoid-Based Anti-Infective Platform Directed Against Drug-Resistant Organisms
NEMUS Bioscience, Inc. (NMUS) announced that the company had signed a licensing agreement with the University of Mississippi (UM) for a platform of cannabinoid-based molecules (UM5070) for potential anti-infective use against bacteria, viruses, and fungi.

Catalent to Develop Softgel Capsules for JOT's Leading Orphan Disease CandidatesCatalent to Develop Softgel Capsules for JOT's Leading Orphan Disease Candidates
Catalent Pharma Solutions recently announced that it is to evaluate Jupiter Orphan Therapeutics, Inc.’s (JOT) novel formulation of resveratrol, JOTROL, for delivery using Catalent’s R.P. Scherer softgel technology.

Cartridge Filling: Combination Features That Can Help Gain a Competitive EdgeCartridge Filling: Combination Features That Can Help Gain a Competitive Edge
By 2050, it is projected that the proportion of people aged 65 and older will be more than double that of children aged 5. This global phenomenon is also leading to an increasing number of people suffering from chronic diseases, such as diabetes and osteoporosis.

Leading Developer of Multi-Layer Oral Thin Film Completes Going Public TransactionLeading Developer of Multi-Layer Oral Thin Film Completes Going Public Transaction
CURE Pharmaceutical, a pre-eminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, recently announced the completion of a going public transaction and the issuance of its new stock symbol - CURR.

Dalton Enters Into Agreement With USAMMDA in Support of US Army’s Drug Development ProgramDalton Enters Into Agreement With USAMMDA in Support of US Army’s Drug Development Program
Dalton Pharma Services, a privately owned pharmaceutical services provider, recently announced that it has entered into a contract service agreement with the United States Army Medical Materiel Development Activity (USAMMDA) in support of the US Army’s product development program for the treatment of severe or complicated malaria due to Plasmodium falciparum.

Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma & Consumer Healthcare Industries Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma & Consumer Healthcare Industries
Lonza Group AG, KKR, and Capsugel S.A. recently announced they have entered into a definitive agreement under which Lonza will acquire Capsugel from KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion, through a transaction that has been approved by the Boards of Directors of both Lonza and Capsugel.

Vetter's Skokie Site Successfully Manufactures Batches on New Clinical Syringe Filling Line Vetter's Skokie Site Successfully Manufactures Batches on New Clinical Syringe Filling Line
Vetter, a leading international contract development and manufacturing organization (CDMO) that specializes in aseptic filling for its (bio-)pharmaceutical customers, recently announced that its new clinical syringe line has already manufactured for its customers a double digit number of batches for use in early clinical trials.

Catalent Biologics Collaborates With PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine R&DCatalent Biologics Collaborates With PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine R&D
Catalent Pharma Solutions recently announced it has signed an agreement with PATH, an international non-profit organization and a leader in global health innovation, to advance a project funded by its Malaria Vaccine Initiative (MVI).

Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI).

West Announces Expanded Contract Manufacturing Capabilities in IrelandWest Announces Expanded Contract Manufacturing Capabilities in Ireland
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, recently announced the completion of a 60,000 square foot expansion at its contract manufacturing facility near Mulhuddart, County Dublin.

Vetter: Choosing the Right Diluent to Help Maximize Success   Vetter: Choosing the Right Diluent to Help Maximize Success
The biologics market continues to rise, expecting to reach $250 billion by 2024. Due to the unstable nature and limited shelf life of many biopharmaceutical compounds, there is an increase in the demand for lyophilized drugs.

Healthcare Companies Must Embrace New Funding Sources as Venture Investment Continues to Decline Healthcare Companies Must Embrace New Funding Sources as Venture Investment Continues to Decline
Although the life sciences industry remains an attractive investment area, the healthcare sector has seen a decline in venture investments, particularly for early stage investments, as pricing pressures, stringent regulations, rising development costs, reimbursement issues, and declining R&D productivity have proved significant barriers, says business intelligence provider GBI Research.

Ligand Partners Spectrum Pharmaceuticals & Lundbeck Receive FDA Approvals Ligand Partners Spectrum Pharmaceuticals & Lundbeck Receive FDA Approvals
Ligand Pharmaceuticals Incorporated recently announced that partners Spectrum Pharmaceuticals (EVOMELA) and Lundbeck (CARNEVIX) received US FDA Approval.

Evonik Ramps Up Production Capacity for Biomaterials Evonik Ramps Up Production Capacity for Biomaterials
Evonik is expanding its production facilities to create additional capacity for the production of biodegradable polymers marketed globally under the brand names RESOMER® and RESOMER® SELECT.

MilliporeSigma Launches Next-Generation Technology for Advanced Live Cell ImagingMilliporeSigma Launches Next-Generation Technology for Advanced Live Cell Imaging
MilliporeSigma has launched the CellASIC ® ONIX2 Microfluidic System for advanced live cell imaging. The system converts laboratory microscopes into powerful tools for live cell imaging to more effectively perform in-depth analysis of cellular mechanisms and behavior in a live environment.

Business Development Manager Needed at FarevaBusiness Development Manager Needed at Fareva
Fareva is looking for a Business Development Manager/Director for the Northern American market, based in NJ, NYC, and CT, to manage its injectables/ophthalmics/high potent businesses. The candidate should have at least 7 years of experience in technical sales in the pharmaceutical industry. Please visit www.fareva.com and contact Ed Saxman for further information at ESaxman@hobbstowne.com

Cancer Vaccines Market Will Soar to $7.5 Billion by 2022Cancer Vaccines Market Will Soar to $7.5 Billion by 2022
The cancer vaccines market is set to almost triple from $2.5 billion in 2015 to $7.5 billion by 2022, representing a strong compound annual growth rate of 16.93%, according to business intelligence provider GBI Research.

Metrics: Stability Storage Facility Q&AMetrics: Stability Storage Facility Q&A
Metrics Contract Services recently announced it is investing $3.5 million to build a dedicated, 15,000-square-foot stability storage facility that will triple the organization’s current storage capacity. In a Q & A, Executive Vice President John S. Ross discusses the new facility and what it means to the organization.

Celyad's CAR-T Candidate Delivers in Early Stage Study Celyad's CAR-T Candidate Delivers in Early Stage Study
Celyad recently announced that first data analysis of the NKR-2 Phase I trial shows encouraging results. The NKR-2 Phase I trial is a single infusion, dose escalation study evaluating the safety and feasibility of NKR-2 T-cells in Acute Myeloid Leukemia and Multiple Myeloma patients.

Progenics Announces $50-Million Infusion to Advance Portfolio Progenics Announces $50-Million Infusion to Advance Portfolio
Progenics Pharmaceuticals, Inc. recently announced its wholly owned subsidiary MNTX Royalties Sub LLC has entered into a $50-million term loan agreement with a fund managed by HealthCare Royalty Partners (HCR) secured by, and to be repaid from, royalties from future sales of RELISTOR.

Positive Results for Alkermes' Phase III Study Spell Good News for Major Depressive Disorder SpacePositive Results for Alkermes' Phase III Study Spell Good News for Major Depressive Disorder Space
Positive topline results have been announced by Alkermes for its Phase III study of ALKS-5461 as an adjunctive therapy for major depressive disorder (MDD), according to research and consulting firm GlobalData.

Viral Gene Announces Breakthrough in Colon CancerViral Gene Announces Breakthrough in Colon Cancer
Drs. Scott Waldman and Adam Snook, along with their research team, have pioneered an innovative vaccine to stop the spread (metastases) of cancers originating in the gastrointestinal tract, including cancers of the colon, rectum, pancreas, stomach, and esophagus.

Molex Completes Acquisition of Phillips-Medisize CorporationMolex Completes Acquisition of Phillips-Medisize Corporation
Molex, a global manufacturer of complete interconnect solutions, has completed its previously announced acquisition of Phillips-Medisize Corporation, a portfolio company of the San Francisco, CA-based private equity investment firm, Golden Gate Capital. Phillips-Medisize will operate as an indirect subsidiary of Molex, LLC.

Catalent Celebrates Ground Breaking for Expanded BiologicsCatalent Celebrates Ground Breaking for Expanded Biologics
Catalent Pharma Solutions recently celebrated its ground breaking for a new $34-million extension to its state-of-the-art Madison, WI, biologics manufacturing facility this past week.

CordenPharma Announces Completion of New Highly Potent API Process Bay for Category 4 Compounds CordenPharma Announces Completion of New Highly Potent API Process Bay for Category 4 Compounds
As part of a long term growth strategy designed to meet increasing customer demands, CordenPharma has completed a recent key investment to strengthen development and manufacturing capabilities for API offerings across its Highly Potent & Oncology Platform.

Phillips-Medisize & Medicom to Showcase Capabilities on Connected Devices at PDA Universe of Pre-Filled Syringes & Injection Devices Phillips-Medisize & Medicom to Showcase Capabilities on Connected Devices at PDA Universe of Pre-Filled Syringes & Injection Devices
Phillips-Medisize Corporation, along with Medicom Innovation Partner will showcase their capabilities at next week’s PDA Universe of Pre-filled Syringes and Injection Devices conference in Huntington Beach, CA. This conference brings together industry and regulatory experts to share their experiences with the benefits, convenience, and innovations pre-filled syringes and injection devices.

Catalent Biologics Announces Agreement With Moderna TherapeuticsCatalent Biologics Announces Agreement With Moderna Therapeutics
Catalent Pharma Solutions recently announced it has entered into an agreement with Moderna Therapeutics to support near-term clinical Good Manufacturing Practice (GMP) messenger RNA (mRNA) manufacturing efforts for Phase 1/2 clinical studies of the company’s mRNA personalized cancer vaccines.

Global Market for Glycobiology to Reach Double Digit CAGRS in All SegmentsGlobal Market for Glycobiology to Reach Double Digit CAGRS in All Segments
New tools for synthesizing, modifying and studying oligosaccharides and glycoconjugates are charging the global glycobiology market. BCC Research reveals in its new report that the field of glycobiology offers enormous untapped potential in the discovery of new therapeutics.

Cardiovascular Disease Market Set to Grow Very Slowly to $146.4 Billion Cardiovascular Disease Market Set to Grow Very Slowly to $146.4 Billion
The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022, at a very modest compound annual growth rate of 1.8%, according to business intelligence provider GBI Research.

Gastrointestinal Drugs Market to Hit $48.4 Billion Gastrointestinal Drugs Market to Hit $48.4 Billion
The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth rate of 4.45%, according to business intelligence provider GBI Research.

Lupin Pharmaceutical Inc. & MonoSol Rx Enter Strategic Licensing Agreement to Develop Multiple Products Lupin Pharmaceutical Inc. & MonoSol Rx Enter Strategic Licensing Agreement to Develop Multiple Products
Lupin Pharmaceutical Inc., the US subsidiary of pharma major Lupin Limited (collectively Lupin) and MonoSol Rx, a specialty pharmaceutical company have entered into a strategic licensing agreement wherein Lupin would develop multiple pediatric products utilizing MonoSol Rx's proprietary PharmFilm ® drug delivery technology.

Biologics Candidate Manufactured Using Ajinomoto’s CORYNEX® Protein Expression System Enters Clinical Trials for the First TimeBiologics Candidate Manufactured Using Ajinomoto’s CORYNEX® Protein Expression System Enters Clinical Trials for the First Time
Ajinomoto Althea, Inc. (Althea) announced that a biologics candidate developed by a Japanese global pharmaceutical company and manufactured at Ajinomoto Althea using CORYNEX ® Protein Expression System, has entered phase I clinical trials.

​Adare Pharmaceuticals Celebrates Corporate Headquarters Grand Opening​Adare Pharmaceuticals Celebrates Corporate Headquarters Grand Opening
Adare Pharmaceuticals, a private global specialty pharmaceutical company, celebrated the official opening of its Corporate Headquarters located at 1200 Lenox Drive in Lawrenceville, New Jersey.

"Engineering Medicines to Life" Campaign Highlights Capsugel's Unique Positioning as Specialty CDMO"Engineering Medicines to Life" Campaign Highlights Capsugel's Unique Positioning as Specialty CDMO
After successfully completing four transformational acquisitions, as well as several other strategic investments, Capsugel today announced that it has unified them all under one brand and unveiled a new corporate campaign that highlights the company’s expanded capabilities for the design, development and manufacture of a wide range of innovative dosage forms.

Bristol-Myers Squibb & Nektar Therapeutics Announce Oncology Clinical Collaboration Bristol-Myers Squibb & Nektar Therapeutics Announce Oncology Clinical Collaboration
Bristol-Myers Squibb Company and Nektar Therapeutics recently announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational medicine, NKTR-214, as a potential combination treatment regimen in five tumor types and seven potential indications.

Australian Pharmaceutical Market to Surpass $25 Billion Australian Pharmaceutical Market to Surpass $25 Billion
Australia’s pharmaceutical market is set to rise from just over $22.85 billion in 2016 to $25.2 billion by 2020, registering a compound annual growth rate (CAGR) of 2%, according to research and consulting firm GlobalData.

Virtual Pharma Companies: The Future is Now Virtual Pharma Companies: The Future is Now
Given a number of continuing industry pressures — including greater diversity of pharma R&D sponsors, looming patent expirations and increased focus on outcomes-based patient care — the virtual pharmaceutical model is proving to be successful, says Tom Salus, director of sales at Metrics Contract Services.

Amyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based ProductsAmyris & Ginkgo Bioworks Complete Collaboration Agreement to Accelerate Commercialization of Bio-Based Products
Amyris, Inc., the industrial bioscience company, recently announced that it has completed a subsequent collaboration agreement with Ginkgo Bioworks, which is expected to be approved by the boards of both companies.

Voyager Therapeutics Licenses Novel Gene Therapy Capsids From the California Institute of TechnologyVoyager Therapeutics Licenses Novel Gene Therapy Capsids From the California Institute of Technology
Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), recently announced a co-exclusive worldwide license agreement with the California Institute of Technology (Caltech) related to novel adeno-associated virus (AAV) capsids.

Epizyme Earns $6-Million Milestone Payment From GlaxoSmithKline Epizyme Earns $6-Million Milestone Payment From GlaxoSmithKline
Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, recently announced it has earned a $6-million milestone payment from GlaxoSmithKline (GSK).

Gerresheimer to Sell Life Science Research Business Gerresheimer to Sell Life Science Research Business
In line with its strategy of focusing on packaging and device solutions for pharmaceutical customers, Gerresheimer recently announced that it is to sell its Life Science Research business to Duran group, a portfolio company of One Equity Partners.

Bayer Clinches Monsanto With Improved $66-Billion BidBayer Clinches Monsanto With Improved $66-Billion Bid
German drugs and crop chemicals company Bayer has won over US seeds firm Monsanto with an improved takeover offer of around $66 billion, ending months of wrangling after increasing its bid for a third time.

Niagara University Faculty Present Groundbreaking Research, New Insulin Pill For Diabetes Patients Niagara University Faculty Present Groundbreaking Research, New Insulin Pill For Diabetes Patients
The need for painful insulin injections by certain diabetes patients may be eliminated with the introduction of a new technique for oral insulin delivery developed by scientists at Niagara University in upstate New York. Niagara faculty members, Mary McCourt, Ph.D., Lawrence Mielnicki, Ph.D., and undergraduate student Jamie Catalano, presented their development at the 252nd National Meeting & Exposition of the American Chemical Society, the world's largest scientific society, in Philadelphia.

Aptar Pharma Announces Development & License Agreement With BDAptar Pharma Announces Development & License Agreement With BD
Aptar Pharma, a leading drug delivery solutions provider and segment of AptarGroup, Inc. (NYSE: ATR) recently announced the signing of an exclusive development and license agreement with BD (Becton, Dickinson and Company) to jointly develop a novel auto-injector using Aptar Pharma’s high-performance, two-step auto-injector technology and prefillable syringes from BD.

CordenPharma Chenôve Receives Successful FDA Inspection CordenPharma Chenôve Receives Successful FDA Inspection
CordenPharma is pleased to announce that their CordenPharma Chenôve (France) manufacturing facility recently completed an FDA Inspection and received a successful response with no 483s reported. The last FDA Inspection took place in 2014.

AMRI Licenses CRISPR-Cas9 Gene Editing Technology AMRI Licenses CRISPR-Cas9 Gene Editing Technology
AMRI recently announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology and has completed several projects for its customers. The company will continue to use the technology to enhance its drug discovery service offerings and internal research and development. Financial terms were not disclosed.

Cell Medica & University College London Collaborate to Develop Modified T Cell Receptor Products for the Treatment of Cancer Cell Medica & University College London Collaborate to Develop Modified T Cell Receptor Products for the Treatment of Cancer
Cell Medica announces new research collaboration with UCL (University College London), which will see the company utilize UCL’s novel T cell receptor (TCR) technology to generate leading-edge modified TCR products for the treatment of cancer.

ACG ACPL Becomes the First Empty Hard Capsule Manufacturer in Asia to Receive EXCiPACT™ CertificationACG ACPL Becomes the First Empty Hard Capsule Manufacturer in Asia to Receive EXCiPACT™ Certification
ACG Worldwide is pleased to announce that ACG Associated Capsules Pvt. Ltd. (ACG ACPL) has received EXCiPACT™ certification for its plant at Dahanu - Maharashtra, India. ACG ACPL is the first empty hard capsule manufacturing company in Asia to receive EXCiPACT™ certification.

Cystic Fibrosis Therapies Will Push Vertex Ahead of GSK in $46.6-Billion Respiratory MarketCystic Fibrosis Therapies Will Push Vertex Ahead of GSK in $46.6-Billion Respiratory Market
The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably from $28.1 billion in 2015 to $46.6 billion by 2022, at a compound annual growth rate (CAGR) of 7.5%, according to business intelligence provider GBI Research.

Novel Lipid-Altering Therapies Will Steer ACS Market Beyond $12 Billion Novel Lipid-Altering Therapies Will Steer ACS Market Beyond $12 Billion
The launch of several new lipid-targeting therapies that offer clinical effectiveness for statin-intolerant patients and patients who require additional lowering of low-density lipoprotein C (LDL-C) in combination to statin therapy, will drive the ACS market, according to research and consulting firm GlobalData.

Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall pharmaceutical industry pipeline as of Q1 2016, according to business intelligence provider GBI Research.

Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & AllerganMayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat irregular heartbeats, such as atrial fibrillation and atrial flutter.......

MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release InjectablesMilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
MilliporeSigma has entered into an agreement with PCAS S.A. (Longjumeau, France) to expand MilliporeSigma's excipients portfolio. Under the agreement, MilliporeSigma will be the exclusive, global distributor of the Expansorb® line of biocompatible and biodegradable polymers.

West’s SmartDose(®) Drug Delivery Technology Platform Selected by Amgen for Pushtronex™ SystemWest’s SmartDose(®) Drug Delivery Technology Platform Selected by Amgen for Pushtronex™ System
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, recently announced that the U.S. Food and Drug Administration (FDA) has approved the first combination product that incorporates its SmartDose ® technology for use in the United States.

Catalent to Commercially Supply Palatin Technologies’ New Bremelanotide FSD Product in Pen InjectorsCatalent to Commercially Supply Palatin Technologies’ New Bremelanotide FSD Product in Pen Injectors
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has reached a commercial supply agreement with Palatin Technologies, Inc., to support the global commercial product launch of Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD).

Major Players in Type 2 Diabetes Shifting Focus to Pricing to Maintain Market ShareMajor Players in Type 2 Diabetes Shifting Focus to Pricing to Maintain Market Share
The highly mature type 2 diabetes (T2D) market, which is forecast to be valued at $58.7 billion by 2025, will see pharmaceutical companies prioritizing competitive pricing in order to offset the impact of patent expiries ahead of improving existing products, says research and consulting firm GlobalData.

Co-Processed Excipients Benefit Market, Offer OpportunityCo-Processed Excipients Benefit Market, Offer Opportunity
The excipients market is pharmaceutical manufacturing dependent, and the demand for excipients is constantly changing according to the production needs of manufacturers’ business strategies, marketing environments, and consumer demand.

Hearty CAGRs for Global Cardiac Biomarker MarketHearty CAGRs for Global Cardiac Biomarker Market
The global cardiac biomarker market should see excellent growth rates among major regions due to the growing prevalence and incidence rates of cardiac diseases. BCC Research reveals in its new report that the Asia-Pacific (APAC) region, in particular, should see a substantial growth rate percentage well into the teens.

Pharmaceutical Industry Licensing Deals Soared to Record $46.2 Billion in 2015Pharmaceutical Industry Licensing Deals Soared to Record $46.2 Billion in 2015
Licensing deal values in the pharmaceutical industry rose by 37.1% year-to-year, from $33.7 billion in 2014 to $46.2 billion in 2015, driven primarily by Sanofi, which struck three licensing deals that totaled nearly $9 billion, according to research and consulting firm GlobalData.

Q&A: Scientific Advances Address Challenges Posed by Poor Solubility of Drug CandidatesQ&A: Scientific Advances Address Challenges Posed by Poor Solubility of Drug Candidates
At Metrics Contract Services, Dr. Michael DeHart manages all aspects of personnel and operations relating to formulating and manufacturing a client’s pharmaceutical materials for Phase I, II and III clinical trials. In this article, Dr. DeHart discusses how scientific advances are addressing challenges posed by the poor solubility or stability of drug candidates.

Pharmaceutical Companies Increasingly Looking to Innovate High-Risk, First-In-Class Products Pharmaceutical Companies Increasingly Looking to Innovate High-Risk, First-In-Class Products
With the cost of bringing a single novel drug to market estimated to be $2.6 billion in 2015, pharmaceutical companies are increasingly looking towards developing first-in-class treatments to maximize revenue and stay ahead of competition, according to business intelligence provider GBI Research.

​​Is Your Plastic Material Suitable for Pharmaceutical Use?​​Is Your Plastic Material Suitable for Pharmaceutical Use?
If you are considering registering plastic material with the FDA in a Drug Master File (DMF), evaluating the safety of that plastic is key.

Global Type 2 Diabetes Market Set to Almost Double to $58.7 BillionGlobal Type 2 Diabetes Market Set to Almost Double to $58.7 Billion
The global type 2 diabetes market is set to almost double from $31.2 billion in 2015 to $58.7 billion by 2025, representing a compound annual growth rate of 6.5%, according to research and consulting firm GlobalData.

West Introduces 1- to 3-mL NovaPure® Plunger for Higher Volume InjectionsWest Introduces 1- to 3-mL NovaPure® Plunger for Higher Volume Injections
West Pharmaceutical Services, Inc. recently announced the availability of the 1- to 3-mL NovaPure® plunger — an innovative, high-quality component for prefilled delivery systems, designed to reduce particulate, ensure consistency of delivery, and fit the changing needs of higher-volume injectable drug delivery systems

Gerresheimer Presents New COP Syringes Produced in Germany: Gx RTF ClearJect Gerresheimer Presents New COP Syringes Produced in Germany: Gx RTF ClearJect
On the occasion of this year's customer trade show, Gerresheimer Pharma Days held in Chicago, Illinois, the company presented the first product of its newly developed Gx RTF ClearJect brand: a COP syringe with cannula.

New Merger Between Pfizer & Anacor Set to Leverage Companies in Atopic Dermatitis SpaceNew Merger Between Pfizer & Anacor Set to Leverage Companies in Atopic Dermatitis Space
An upcoming merger agreement between Pfizer and Anacor, worth around $5.2 billion, could boost the marketing power of Anacor’s lead pipeline candidate, crisaborole, and pave the way for Pfizer to launch its own candidate, a topical form of Xeljanz, both for the treatment of mild-to-moderate atopic dermatitis, according to an analyst with research and consulting firm GlobalData.

The Promise of Stem Cell Research Yields Double-Digit Growth RatesThe Promise of Stem Cell Research Yields Double-Digit Growth Rates
Although products based on stem cells have yet to form an established market, unlike some other potential applications of bioscience, stem cell technology has already produced a number of significant products in important therapeutic areas. BCC Research reveals in its new report that researchers around the world are using stem cells to achieve new outcomes that will mark a paradigm shift in drug discovery and the medicine world.

Technology Advancements in Protein Therapeutics Spurring Market Growth to $248.7 BillionTechnology Advancements in Protein Therapeutics Spurring Market Growth to $248.7 Billion
Protein drugs have gained importance for their therapeutic applications, and the numbers of products have increased in recent years. BCC Research reveals in its new report that novel technologies, such as recombinant DNA (recombinant deoxyribonucleic acid or rDNA) technology and genetic engineering, have lifted the market for protein drugs to new heights.

Ajinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal AntibodiesAjinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies
Ajinomoto Althea Inc., a leading provider of biotherapeutic contract development and manufacturing services, today announced that the United States Patent and Trademark Office has issued US Patent 9,310,379 covering methods to crystallize monoclonal antibodies for the purpose of scale up and cGMP manufacturing for therapeutic use. The patented methods are important for successful stabilization, storage and delivery of biologically active antibody crystals.

Capsugel Expands Micro-Dosing Services to Help Accelerate Customers' Product Development Timelines Capsugel Expands Micro-Dosing Services to Help Accelerate Customers' Product Development Timelines
Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced that it is expanding its micro-dosing services offering for early-phase feasibility work. Capsugel’s offering combines its proprietary Xcelodose ® Precision Powder Micro-Dosing Systems with industry-leading powder-in-capsule/powder-in-bottle (PIC/PIB) expertise developed at Xcelience, which Capsugel acquired in January.

Aptar Pharma's Preservative-Free Multi-Dose Ophthalmic Squeeze Dispenser Launched in USAptar Pharma's Preservative-Free Multi-Dose Ophthalmic Squeeze Dispenser Launched in US
Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, has partnered with a leading eye care company to develop and launch a new eye drop product, which uses Aptar Pharma’s innovative preservative free multi-dose Ophthalmic Squeeze Dispenser (OSD).

Dublin-Based Innopharma Technology Announces Strategic Collaboration With Glatt Dublin-Based Innopharma Technology Announces Strategic Collaboration With Glatt
Dublin-based Innopharma Technology and Glatt (India) Systems Pvt. Ltd. have recently announced a strategic collaboration that is set to reduce product manufacturing costs while increasing compliance and product quality for the pharmaceutical, MedTech, and food industries.

Disease-Modifying Drugs Will Propel Huntington’s Disease Market to $2.6 Billion Disease-Modifying Drugs Will Propel Huntington’s Disease Market to $2.6 Billion
The Huntington’s disease market will rise from around $252.6 million in 2014 to over $2.6 billion in 2024, representing a huge Compound Annual Growth Rate (CAGR) of 25.6%, according to research and consulting firm GlobalData.

Meggle Announces New Head of Sales & MarketingMeggle Announces New Head of Sales & Marketing
The Business Group Excipients & Technology of MEGGLE announced the appointment of Dr. Albrecht Kraemer, as its new Head of Sales & Marketing as of April 1, 2016

Heart Failure Market to Soar to $11.8 Billion by 2025 Heart Failure Market to Soar to $11.8 Billion by 2025
The heart failure market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, representing a compound annual growth rate of 13.7%, according to research and consulting firm GlobalData.

Comparative Human In Vivo Study of an Immediate-Release Tablet Over-Encapsulated by Gelatin & Hydroxypropyl Methyl Cellulose Capsules – Impact of Dissolution Rate on BioequivalenceComparative Human In Vivo Study of an Immediate-Release Tablet Over-Encapsulated by Gelatin & Hydroxypropyl Methyl Cellulose Capsules – Impact of Dissolution Rate on Bioequivalence
Rapid and consistent in-vivo drug dissolution is critical for drug absorption. In-vitro dissolutions tests are used to predict in-vivo disintegration and dissolution properties of drug products...

​INTERPHEX & Industry Experts Select Nemera as Winner for Best New Product ​INTERPHEX & Industry Experts Select Nemera as Winner for Best New Product
International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology, and knowledge from development through commercialization and sponsored by the Parenteral Drug Association (PDA), has announced the winners for the INTERPHEX Exhibitor Awards for 2016.

First Gene Therapy Claims to be Successful Against Human AgingFirst Gene Therapy Claims to be Successful Against Human Aging
Elizabeth Parrish, CEO of Bioviva USA Inc. has become the first human being to be successfully rejuvenated by gene therapy, after her own company’s experimental therapies reversed 20 years of normal telomere shortening.

Bristol-Myers Squibb & Merck in Race to Dominate Head & Neck Cancer MarketBristol-Myers Squibb & Merck in Race to Dominate Head & Neck Cancer Market
Bristol-Myers Squibb (BMS) and Merck & Co. are set to continue their strong rivalry in the head and neck cancer space, as their respective PD-1 inhibitory monoclonal antibodies, Opdivo and Keytruda, race to enter the market, according to an analyst with research and consulting firm GlobalData.

Multi-Blockbuster Drugs Will Drive Immuno-Oncology Market to $34 Billion by 2024Multi-Blockbuster Drugs Will Drive Immuno-Oncology Market to $34 Billion by 2024
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as the treatment of cancer patients undergoes drastic changes over the next decade, according to research and consulting firm GlobalData.

Patheon Selected By Grünenthal to Develop Drugs Using INTAC(R) Abuse-Deterrent Formulations TechnologyPatheon Selected By Grünenthal to Develop Drugs Using INTAC(R) Abuse-Deterrent Formulations Technology
Patheon recently announced it has signed a strategic agreement with Grünenthal to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse-deterrent formulation technology INTAC®.

AAI Pharma Services Corporation & Cambridge Major Laboratories Are Now AlcamiAAI Pharma Services Corporation & Cambridge Major Laboratories Are Now Alcami
AAIPharma Services Corporation (AAI) / Cambridge Major Laboratories, Inc. (CML), a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, recently announced its new brand and identity as a leading contract development and manufacturing organization (CDMO) with expanded capabilities and capacity, the organization to now be known as Alcami.

Aptar Pharma Launches eDose Counter for MDIs Integrating Proprietary Sensing TechnologyAptar Pharma Launches eDose Counter for MDIs Integrating Proprietary Sensing Technology
Aptar Pharma, a global solution provider of innovative and proven aerosol, injection, and spray delivery systems for biotech, healthcare, and pharma products, will unveil its latest innovation, the eDose Counter for metered dose inhalers (MDIs), at the RDD scientific conference in Phoenix, AZ, from April 18-21, 2016.

World Excipients Market Expected to Reach $6.4 Billion by 2020World Excipients Market Expected to Reach $6.4 Billion by 2020
A new report published by Allied Market Research titled World Excipients Market-Opportunities and Forecasts, 2014-2020 projects that the world excipients market would reach $6.4 billion by 2020 at a CAGR of 7.6% during 2015 and 2020. Organic chemicals would continue to be the highest revenue-generating segment during the forecast period.

Global Viral Infections Market to Reach $117.6 Billion Global Viral Infections Market to Reach $117.6 Billion
The global viral infections market will grow from $74 billion in 2014 to $117.6 billion by 2021, representing a compound annual growth rate of 6.8%, according to business intelligence provider GBI Research.

WellSpring Pharma Services Completes $3-Million Capital Investment & Forms New Partnership WellSpring Pharma Services Completes $3-Million Capital Investment & Forms New Partnership
WellSpring Pharma Services, leading specialists in formulation, development and manufacturing for a wide range of solid, semi-solid and non-sterile liquid products, has announced a $3 million capital investment in new equipment as well as a new strategic partnership with IDT Australia Ltd. to manufacture drugs targeting the U.S. market.

Huge Opportunities Remain for Premium-Priced Tyrosine Kinase Inhibitors in Pulmonary Arterial HypertensionHuge Opportunities Remain for Premium-Priced Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension
The Pulmonary Arterial Hypertension (PAH) space, which is currently burdened by significant unmet need, could benefit substantially from a class of drugs known as Tyrosine Kinase Inhibitors (TKIs), which may aid development of a disease-modifying drug, according to an analyst with research and consulting firm GlobalData.

Paragon Bioservices Recognized as Best Contract Manufacturing Organization Paragon Bioservices Recognized as Best Contract Manufacturing Organization
Paragon Bioservices, Inc., a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today that it was selected as the "Best Contract Manufacturing Organization" by the World Vaccine Congress, at its annual meeting held in Washington, D.C. last week.

Crown Bioscience Strengthens Immuno-Oncology Capabilities With HuGEMMCrown Bioscience Strengthens Immuno-Oncology Capabilities With HuGEMM
Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, is pleased to announce that it has developed and validated a unique set of models for immuno-oncology called HuGEMM™.

Exclusive: Capsugel Prepares to Explore Sale or IPO Exclusive: Capsugel Prepares to Explore Sale or IPO
Capsugel, a U.S. maker of capsule products and other drug delivery systems, is preparing to explore a sale or initial public offering that could value it at more than $5 billion including debt, according to people familiar with the matter.

Ascendia Pharma Announces New Contract Manufacturing Capability to Deliver cGMP Phase I Clinical Trial MaterialsAscendia Pharma Announces New Contract Manufacturing Capability to Deliver cGMP Phase I Clinical Trial Materials
Ascendia now offers cGMP manufacturing capabilities for both oral and parenteral dosage forms to support your Phase I clinical trials. We have recently finished the qualification of cleanrooms suitable for manufacture of solid oral dosage forms and injectable drugs (via terminal sterilization by autoclave or aseptic filtration).

Gastric Cancer Drug Development Shifting From Small Molecules to Monoclonal AntibodiesGastric Cancer Drug Development Shifting From Small Molecules to Monoclonal Antibodies
While 99% of currently marketed gastric cancer drugs are small molecules, this dominance could give way to more innovative treatments in future, as the pipeline consists of 29% monoclonal antibodies (mAbs), according to business intelligence provider GBI Research.

Formulation Development Success Story: Uric Acid Treatment Approved by FDAFormulation Development Success Story: Uric Acid Treatment Approved by FDA
The U.S. Food and Drug Administration recently approved a new uric acid treatment that was developed as a partnership between Metrics Contract Services and the project sponsor.

Glioblastoma Treatment Hopes Turn to Combining Peptide Vaccines With Immuno-Oncology ProductsGlioblastoma Treatment Hopes Turn to Combining Peptide Vaccines With Immuno-Oncology Products
The termination of Celldex’s Phase III trial assessing its peptide-based vaccine therapy, Rintega, in newly diagnosed glioblastoma patients, represents a blow to the treatment space as hopes for improved therapies turn instead to Opdivo and drugs combining peptide vaccines with immuno-oncology products, according to analysts with research and consulting firm GlobalData.

Nitrogen Dioxide Sterilization: Maintains Prefilled Syringe IntegrityNitrogen Dioxide Sterilization: Maintains Prefilled Syringe Integrity
A recent study demonstrates low temperature NO2 as an optimal process to surface sterilize prefilled syringes while maintaining container closure integrity. The sterilant did not diffuse past the barrier. Noxilizer provides an assay for NO2 sterilization as a means of demonstrating container closure integrity during validation. It is one piece of information that prefilled syringe manufacturers can use to bolster their regulatory submissions.

Strong Life Sciences Sector Will Drive UK Pharmaceutical Market to $43 Billion Strong Life Sciences Sector Will Drive UK Pharmaceutical Market to $43 Billion
The pharmaceutical market in the UK is set to grow from $28.8 billion in 2015 to approximately $43 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 8.4%, driven primarily by a robust life sciences industry, according to research and consulting firm GlobalData.

West Appoints Eric Resnick to Chief Technology OfficerWest Appoints Eric Resnick to Chief Technology Officer
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, recently announced Eric Resnick has been appointed to serve as Vice President and Chief Technology Officer, succeeding John Paproski, who plans to retire on April 1, 2016.

ICIG to Acquire All Shares in Sandoz Industrial Products ICIG to Acquire All Shares in Sandoz Industrial Products
International Chemical Investors Group (ICIG) and Novartis Group have entered into an agreement under which ICIG will acquire all of the shares in Sandoz Industrial Products GmbH, a Frankfurt-Höchst-based manufacturer of enzyme-based fermentation products and intermediates for the pharmaceutical industry, especially for the use in antibiotics. Closing of the transaction is anticipated to occur April 1, 2016.

How the Need for an Alternative Oral Dosage Form Delivered a Patient-Centric Drug FormulationHow the Need for an Alternative Oral Dosage Form Delivered a Patient-Centric Drug Formulation
Dysphagia can affect many people throughout their lifetime. It also represents a challenge for oral drug manufacturers. Dysphagia not only impacts patients’ ability to take solid oral dosage forms, but it can also compromise adherence. When it comes to drug development, there is value in developing medicines that are tailored to patients’ needs. This paper discusses the patient-centric approach of Adare Pharmaceuticals—experts in creating formulations that solve unmet patient needs, such as dysphagia.....

Unilife & Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems; Amgen to Invest up to $75 Million Unilife & Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems; Amgen to Invest up to $75 Million
Unilife Corporation recently announced a strategic collaboration with Amgen for injectable drug delivery systems. The collaboration, which includes licensing, investment, development, and supply agreement components, is centered upon the use of Unilife's portfolio of prefilled, customizable wearable injectors for medicines to enhance the patient experience.

Hype Surrounding Cancer T-Cell Therapy Overlooks Safety & Cost Concerns Hype Surrounding Cancer T-Cell Therapy Overlooks Safety & Cost Concerns
Although excitement surrounding recent trials of T-cell therapies and their ability to treat blood cancer has been widespread of late, there are lingering questions about their marketability, says an analyst with research and consulting firm GlobalData.

Capsugel & Pulmatrix Enter Collaboration to Develop & Manufacture Novel Inhaled TherapeuticsCapsugel & Pulmatrix Enter Collaboration to Develop & Manufacture Novel Inhaled Therapeutics
Capsugel and Pulmatrix, Inc. have recently formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE-based inhaled therapeutic candidates being developed by Pulmatrix and its potential development partners.

West's Daikyo Crystal Zenith® Cyclic Olefin Polymer Selected by AmgenWest's Daikyo Crystal Zenith® Cyclic Olefin Polymer Selected by Amgen
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, recently announced that global biotechnology leader Amgen Inc. has utilized West’s Daikyo Crystal Zenith ® (CZ) vials, in conjunction with West FluroTec ® stoppers, to contain its FDA-approved therapy IMLYGIC™ (talimogene laherparepvec).

NGS & Cloud Computing Driving Big Growth in Global Bioinformatics MarketsNGS & Cloud Computing Driving Big Growth in Global Bioinformatics Markets
Next-generation sequencing (NGS) technology has fueled the genomics revolution, making it possible to sequence an entire human genome within days for a few thousand dollars.

XBiotech Engages in Research for Heart Attack Antibody TherapyXBiotech Engages in Research for Heart Attack Antibody Therapy
XBiotech Inc., developer of True Human™ therapeutic antibodies, announced today the signing of a Material Transfer Agreement (MTA) with Brigham and Women’s Hospital and Massachusetts General Hospital.

Merck’s Zepatier Will Threaten the Dominance of Gilead’s Harvoni in Hepatitis C MarketMerck’s Zepatier Will Threaten the Dominance of Gilead’s Harvoni in Hepatitis C Market
The introduction of Merck and Co.’s recently-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market long-dominated by Gilead. The combination of Zepatier’s excellent clinical profile and highly competitive pricing will play a major role in encouraging its uptake, says an analyst with research and consulting firm GlobalData.

Infusion Pumps That Sense The Drug Flow - And Even Your Heartbeat - In ItInfusion Pumps That Sense The Drug Flow - And Even Your Heartbeat - In It
Sensor technology takes infusion pumps to the next level by making failure detection reliable, even for infiltration. Everyday millions of patients worldwide receive intravenous infusion therapy, many times assisted by a smart infusion pump. Smart infusion pumps provide well-controlled drug delivery over a prolonged period of time and are of tremendous help for hospital staff.

Global Orphan Drug Market to Gain Almost $68 Billion by 2019; Favorable Legislation Spurring R&D
Growing competition, new technologies, improved gene therapies, and favorable legislation and incentives have led the global orphan drug market to experience a significant increase in the number of approved orphan drugs and their market availability. BCC Research reveals in its new report that approval of biological orphan drugs for multiple indications has been a growth factor, along with successful product launches of non-biological drugs.

RNAi Therapeutics Holds Therapeutic Promise for Unmet ConditionsRNAi Therapeutics Holds Therapeutic Promise for Unmet Conditions
Ribonucleic acid interference (RNAi) mechanisms and technologies are being extensively explored in biological applications in order to silence mRNA’s encoding proteins and to develop appropriate therapies. BCC Research reveals in its new report the requirement of treatments for unmet medical conditions has boosted the RNAi mechanisms, which promise to be effective and potent if approved and commercialized after rigorous clinical trials.

Pharma Companies Must Assess Real-World Evidence to Keep Up With Shifts in the Global Market Access LandscapePharma Companies Must Assess Real-World Evidence to Keep Up With Shifts in the Global Market Access Landscape
As the overall costs of drugs continue to increase and pricing pressures shift the dynamics of the healthcare market, pharmaceutical companies must analyze real-world trends in different treatment spaces, and assess existing and expected levels of competition, in order to gain optimal market access, says business intelligence provider GBI Research.

HERMES PHARMA Makes Hot-Melt Coating Available for the Pharma IndustryHERMES PHARMA Makes Hot-Melt Coating Available for the Pharma Industry
HERMES PHARMA, the expert in user-friendly solid oral dosage forms, recently announced the commercial implementation of hot-melt coating (HMC) in its production facility. The implementation of this technology is the result of a research project aimed at developing new pharmaceutical formulations that are stable, effective and user-friendly.

Case Study of Formulating “One & Done” Daily Dosing Involving a Highly Water-Soluble APICase Study of Formulating “One & Done” Daily Dosing Involving a Highly Water-Soluble API
A client sought the help of Metrics Contract Services scientists to develop a palatable “one and done” daily dosage form for its clinical trial involving non-compliant patients. Metrics formulated a controlled-release dosage form for a highly water-soluble compound using a solvent system rather than aqueous dispersion and cure times.

More Than 1 in 4 Novel New Drugs Approved by FDA in 2015 are Personalized MedicinesMore Than 1 in 4 Novel New Drugs Approved by FDA in 2015 are Personalized Medicines
A new analysis from the Personalized Medicine Coalition (PMC) documents an upward trend in the number of personalized medicine approvals at FDA, with personalized medicines accounting for more than 1 in 4 novel new drugs (NNDs) approved in 2015.

Chronic Obstructive Pulmonary Disease Treatment Pipeline Lacks Robust Innovation Chronic Obstructive Pulmonary Disease Treatment Pipeline Lacks Robust Innovation
Despite an influx of new therapies over recent years, the Chronic Obstructive Pulmonary Disease (COPD) treatment market has a number of unmet needs, and the innovation in its product development pipeline is lagging in comparison to other indications, says business intelligence provider GBI Research.

Glioblastoma Treatment Market Will Expand Five-Fold to $3.3 Billion Glioblastoma Treatment Market Will Expand Five-Fold to $3.3 Billion
The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, representing a rapid Compound Annual Growth Rate (CAGR) of 17.4%, according to research and consulting firm GlobalData.

Unilife Surges on Wearable Injector Devices Pact With AmgenUnilife Surges on Wearable Injector Devices Pact With Amgen
Unilife Corporation stock jumped more than 100% this morning after the company announced a new deal with Amgen to develop wearable injector devices.

US Demand for Drug Delivery Products to Reach $251 Billion
Demand for drug delivery products in the US is projected to increase 6.1% annually to $251 billion in 2019. Specialized dosage formulations that improve therapies for autoimmune, cancer, cardiovascular, neurological, viral, and other debilitating disorders will lead gains. Included in this group are human and humanized monoclonal antibodies, polymer-encapsulated medicines, and brachytherapy seeds.

Haselmeier Self-Injection Devices Go ConnectedHaselmeier Self-Injection Devices Go Connected
The innovative and patented technology provides a simple and intuitive solution for patients while creating an integrated device solution with a range of features that include: device ID and authentication, electronic health record integration & remote physician monitoring and interaction.

Nanosphere Announces $10-Million Registered Public Offering Nanosphere Announces $10-Million Registered Public Offering
Nanosphere, Inc. recently announced the pricing of a public offering of the company’s common stock with expected total gross proceeds of approximately $10 million. The offering is expected to close on or about December 22, 2015, subject to satisfaction of customary closing conditions.

Top Pharma Companies’ R&D Returns Continue to SlideTop Pharma Companies’ R&D Returns Continue to Slide
While the Research and Development (R&D) divisions of 12 leading pharmaceutical companies have progressed 306 assets into late-stage pipelines since 2010, with projected lifetime returns of over $1.41 trillion, these returns are continuing to decline in percentage terms, according to a study produced by Deloitte in collaboration with research and consulting firm GlobalData.

Pharmaceutical Deals Crucial to Offsetting $2.5-Billion Cost of Developing a Novel DrugPharmaceutical Deals Crucial to Offsetting $2.5-Billion Cost of Developing a Novel Drug
With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster status, deal-making is becoming increasingly vital for pharmaceutical companies to offset rising Research and Development (R&D) costs, says business intelligence provider GBI Research.

Capsugel to Acquire Xcelience & PowdersizeCapsugel to Acquire Xcelience & Powdersize
Capsugel, Xcelience, and Powdersize recently announced the three companies have entered into a definitive agreement under which Capsugel will acquire both Xcelience and Powdersize. The transaction, which is subject to regulatory approval, will further enhance Capsugel’s position as a leading provider of innovative dosage forms and solutions to healthcare customers around the world.

Pharma Outsourcing M&As Set for Record Year in 2015
A drastic increase in Mergers and Acquisitions (M&A) activity propelled the value of pharmaceutical outsourcing deals from $9.9 billion in 2014 to nearly $17.6 billion through October 2015, putting the sector on track for a record-breaking year, according to an analyst with research and consulting firm GlobalData.

​​Apprentice Field Suite Introduces Apps That Reduce Manufacturing Downtime, Improve Accuracy, & Increase Site & Product Safety​​Apprentice Field Suite Introduces Apps That Reduce Manufacturing Downtime, Improve Accuracy, & Increase Site & Product Safety
AFS has expanded its portfolio of award-winning applications that allows engineers and operators to see and repair manufacturing issues in real time without physically being on-site – reducing downtime, improving accuracy, and increasing site and product safety.

​​Ajinomoto Althea Launches Process & Analytical Development Services for ADC Therapeutics​​Ajinomoto Althea Launches Process & Analytical Development Services for ADC Therapeutics
Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials, such as Antibody Drug Conjugates (ADCs).

Global Immunology Treatment Market Will Exceed $74 Billion by 2022Global Immunology Treatment Market Will Exceed $74 Billion by 2022
Despite the imminent patent expiry of many therapies, the global immunology treatment market is set to expand, from $61.5 billion in 2015 to reach $74.2 billion in 2022, says business intelligence provider GBI Research.

Aptar Pharma Presents a Step Change in the Performance of DF30Plus for PMDIs Incorporating COCAptar Pharma Presents a Step Change in the Performance of DF30Plus for PMDIs Incorporating COC
Aptar Pharma, a global solution provider of innovative and proven aerosol, injection, and spray delivery systems for biotech, healthcare, and pharma products, will present its latest innovation at the Drug Delivery to the Lungs (DDL) scientific conference in Edinburgh, Scotland.

SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to RemodulinSteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin
SteadyMed Ltd., a company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, recently announced the results of a non-clinical animal study, which evaluated the potential effect of the company's preservative-free Trevyent formulation on reducing the significant subcutaneous infusion site pain often associated with United Therapeutics' Remodulin, the market leading prostacyclin used to treat pulmonary arterial hypertension (PAH).

Strongbridge Biopharma Announces Issuance of US Patent for Investigational COR-003 in Treatment of Endogenous Cushing's SyndromeStrongbridge Biopharma Announces Issuance of US Patent for Investigational COR-003 in Treatment of Endogenous Cushing's Syndrome
Strongbridge Biopharma plc recently announced that the United States Patent and Trademark Office (USPTO) issued a patent related to the Company's lead investigational drug candidate, COR-003 (levoketoconazole), a cortisol inhibitor that is currently being studied in a global Phase III trial for the treatment of endogenous Cushing's syndrome.

Pfizer Awards Flagship OTC Product Manufacturing Contract to CatalentPfizer Awards Flagship OTC Product Manufacturing Contract to Catalent
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, recently announced that it has entered into an exclusive long term supply agreement to produce Pfizer Inc.’s leading over-the-counter (OTC) heartburn treatment, Nexium ® 24HR (esomeprazole), also marketed as Nexium Control® outside the United States.

Global Type 1 Diabetes Mellitus Market Value Will Exceed $7 Billion
The Type 1 Diabetes Mellitus (T1DM) market across the eight major countries of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan will expand from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%, according to business intelligence provider GBI Research.

UPM Pharmaceuticals Seeking to Fill 8 PositionsUPM Pharmaceuticals Seeking to Fill 8 Positions
UPM Pharmaceuticals, Inc., a growing contract drug development and manufacturing company, located at Bristol TN, is seeking applicants for 8 positions, including Formulation Associate, GMP Training Manager, Pharmaceutical Tech Engineer, Production Planner, Project Leader, Quality Associate, Quality Assurance Auditor, and Senior Scientist.  

12th Annual BioProcess International Conference & Exposition Is Largest in Its History 12th Annual BioProcess International Conference & Exposition Is Largest in Its History
The BioProcess International (BPI) Conference & Exposition held October 26-29 boasted the largest attendance in the show’s 12-year history, as scientists and engineers representing 36 states and 29 countries gathered in Boston for the global forum. Hosted by IBC Life Sciences USA, an Informa company, the annual event focused on advancing drug candidates closer to approval and bringing together professionals from big pharma as well as large, mid-size and emerging biotech companies.

Xcelience Opens New Headquarters Facility  Xcelience Opens New Headquarters Facility
Xcelience is proud to announce the grand opening of its new 71,000 square foot headquarters located at 4910 Savarese Circle in Tampa. The building houses preformulation and formulation development labs and suites, as well as analytical and stability services. The official ribbon cutting ceremony was attended by Florida Governor Rick Scott, Tampa Mayor Bob Buckhorn and other elected and non-elected officials.

Dow Corning Launches New Portfolio of Topical Ingredients to Help Customers Advance Innovations in Consumer Health Care ApplicationsDow Corning Launches New Portfolio of Topical Ingredients to Help Customers Advance Innovations in Consumer Health Care Applications
Dow Corning, a global leader in silicones, silicon-based technology and innovation, unveiled at the American Association of Pharmaceutical Scientists’ (AAPS) 2015 Annual Meeting and Exhibition its new industry-leading Dow Corning Topical Ingredients portfolio.

New Jersey Company Seeks Formulation ScientistNew Jersey Company Seeks Formulation Scientist
To perform the job successfully, an individual must be able to perform each essential duty satisfactorily. The requirements listed here are representative of the knowledge, skill and/or ability required. Reasonable accommodation may be made to enable individuals with disabilities to perform the essential functions.

Scientific Posters at BPI Spotlight Cutting-Edge Research Scientific Posters at BPI Spotlight Cutting-Edge Research
The 2015 BioProcess International (BPI) Conference & Exposition, hosted by IBC Life Sciences USA, an Informa company, will display over 100 peer-submitted scientific posters, creating an in-depth, interactive experience that connects scientists and executives in bioprocessing, biomanufacturing and cell therapy with leading academic universities and emerging technology companies.

Realizing Process Innovation in Aseptic Manufacturing: An Improved RABS ConceptRealizing Process Innovation in Aseptic Manufacturing: An Improved RABS Concept
(Bio-)pharmaceutical service providers in their role of manufacturing complex drug products face a difficult challenge in providing reliable and repeatable aseptic processes for ever-decreasing batch sizes. The two most commonly used technologies today are isolators, which traditionally are known as the best solution for a high level of sterility, and RABS (restricted access barrier systems), which provide greater flexibility and higher capacity utilization of filling lines when running multiple products.

Astellas Pharma & Immunomic Therapeutics Announce $300-Million Worldwide Partnership for LAMP-vax Products Astellas Pharma & Immunomic Therapeutics Announce $300-Million Worldwide Partnership for LAMP-vax Products
Immunomic Therapeutics, Inc. and Astellas Pharma Inc. recently announced they have entered into an exclusive worldwide license agreement to the LAMP-vax products for the treatment or prevention of any and all allergic diseases in humans. The LAMP-vax technology enhances the effectiveness of DNA vaccines. It has the ability to make DNA vaccines work, which potentially enables effective vaccinations for a wide spectrum of diseases.

Vetter Embarks on a 300 Million Euro Investment Strategy Vetter Embarks on a 300 Million Euro Investment Strategy
Vetter has announced that in keeping with its commitment to providing customers with the manufacture of high quality drug products, the company will invest approximately 300 million euros to expand and upgrade its manufacturing facilities over an estimated five-year period.

 Ultra-Low Flow Technology for Drug Delivery Ultra-Low Flow Technology for Drug Delivery
Mott Corporation has developed a technology that controls the flow rate of a liquid or drug in devices over extended periods of time. This technology can be configured for passive or diffusional flow and can also manage flow rates in powered devices.

Oncology Leads Development in Promising Gene Therapy Pipeline
Despite few products having so far reached the market and captured strong revenues, the gene therapy pipeline remains large, with 906 products in active development across all stages. However, the majority of these remain in early steps of development, with 76% at either the Discovery or Preclinical stage, according to business intelligence provider GBI Research.

Science-Based Technology Selection & Formulation Development for Oral Bioavailability EnhancementScience-Based Technology Selection & Formulation Development for Oral Bioavailability Enhancement
The increasing fraction of poorly water-soluble compounds in pharmaceutical discovery is leading to significant growth in the use of enabling technologies to improve oral drug absorption and bioavailability (BA). Commonly used technologies in this area have been extensively reviewed and include salt selection, cocrystals, amorphous solid dispersions, particle size reduction, cyclodextrins, amorphous/lipid micro- and nanoparticulates, adsorbents and lipid-based technologies.

Benign Prostatic Hyperplasia Treatment Market Value to Reach Nearly $5 Billion
The value of the global therapeutics market for Benign Prostatic Hyperplasia (BPH) will rise from just over $2 billion in 2014 to approximately $4.9 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 8.23%, according to research and consulting firm GlobalData.

Downstream Processing - BioProcess International Conference Pre-Event Podcast SeriesDownstream Processing - BioProcess International Conference Pre-Event Podcast Series
Building on the momentum being gained from the innovation of methodologies, materials science and technologies, companies within the Recovery & Purification track will describe progress being made to optimize efficiencies, process design and flexibility in downstream processing for an emerging wave of antibodies and novel modalities.

Global Non-Small Cell Lung Cancer Treatment Market Value to Approach $11 Billion
The global market value for Non-Small Cell Lung Cancer (NSCLC) treatment will increase from $6.9 billion in 2014 to $10.9 billion by 2021, representing a Compound Annual Growth Rate (CAGR) of 8.5%, says business intelligence provider GBI Research.

Branded Acute Coronary Syndrome Therapies to Grab Market Share From Generic Drugs Globally
The acute coronary syndrome therapeutics market consists of approximately 30 marketed branded drugs and hundreds of generics. While generic ACS drugs currently lead in market revenues, the share of branded therapeutics is expected to increase to more than 60% of the total market due to the development and launch of novel pipeline products between 2015 and 2019.

Antisense RNAi Therapeutics Deals Value Approached $5.6 Billion in Landmark 2014
The deals market for antisense RNA interference (RNAi) therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59 transactions, by far the largest deal value ever seen in this space, according to research and consulting firm GlobalData.

Cell Culture & Upstream Processing - BioProcess International Conference Pre-Event Podcast SeriesCell Culture & Upstream Processing - BioProcess International Conference Pre-Event Podcast Series
The Cell Culture & Upstream Processing Track will feature process development scientists, engineers and technical experts sharing their recent achievements in reducing timelines and cost of goods while increasing efficiency and productivity through implementation of disruptive approaches and technologies.

Life Cycle Management Strategies More Crucial than Ever for Pharmaceutical Success
With shrinking Research and Development (R&D) pipelines and mounting costs involved in drug development, it is becoming increasingly important for pharmaceutical companies to implement suitable Life Cycle Management (LCM) strategies in order to maximize revenues and the lifespan of their portfolios, says business intelligence provider GBI Research.

Former Unilife Employee Issues Apology & Withdraws Whistleblower Lawsuit
Unilife Corporation recently announced that a former employee has agreed to dismiss all of his claims against the Company and has issued a public apology for bringing his claims. The case, Talbot Smith v. Unilife Corp. et al, No. 13-CV-05101, filed in the United States District Court for the Eastern District of Pennsylvania, has been dismissed in its entirety with prejudice.

Brazil’s Pharmaceutical Market Value Will Approach $48 BillionBrazil’s Pharmaceutical Market Value Will Approach $48 Billion
The Brazilian pharmaceutical market will expand in value from $29.4 billion in 2014 to reach approximately $47.9 billion by 2020, representing a strong Compound Annual Growth Rate (CAGR) of 8.5%, according to research and consulting firm GlobalData.

CELLSEARCH System Recognized as Landmark Innovation in Cancer Research CELLSEARCH System Recognized as Landmark Innovation in Cancer Research
Janssen Diagnostics recently announced that a clinical trial involving the company’s CELLSEARCH System has been recognized by the editors of Clinical Cancer Research as being among the most significant studies to appear in the journal in its 20 year history.

Oncology Treatment Offers Significant Opportunities With Largest Pipeline in Pharmaceuticals
The oncology drug pipeline is far larger than any other therapy area across the pharmaceutical industry, with 6,484 products in active development across all indications, suggesting significant opportunities for new market entries, according to business intelligence provider GBI Research.

NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer
NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration (FDA) for a second drug product that uses NanoSmart's proprietary drug delivery platform.

Unilife Introduces World's First Instant Patch Pump for InsulinUnilife Introduces World's First Instant Patch Pump for Insulin
Unilife Corporation, a developer, manufacturer and supplier of injectable drug delivery systems, recently announced the introduction of the Imperium™ platform of instant patch pumps for insulin.

Xcelience Makes Structured Cash Investment in Powdersize Xcelience Makes Structured Cash Investment in Powdersize
Xcelience, a contract development and manufacturing organization (CDMO), recently announced that it has made a structured cash investment in Powdersize, a Pennsylvania-based company specializing in milling, micronization and powder size classification within the pharmaceutical industry.

Pharma, Medical & Biotech Global Trend ReportPharma, Medical & Biotech Global Trend Report
Mergermarket has released its Global Pharma, Medical & Biotech (PMB) trend report for the first half (H1) of 2015.

Vetter Launches Vetter-Ject® - A New Syringe Closure System for Highly Sensitive Compounds Vetter Launches Vetter-Ject® - A New Syringe Closure System for Highly Sensitive Compounds
Vetter recently announced the release of Vetter-Ject®, a novel closure system for prefilled syringes. By this closure part a baked-in siliconization of an integrated needle syringe can be realized. That allows the use in highly-sensitive compounds such as biologics. The tamper-evident closure system, combined with an integrated staked needle, supports the product integrity of Vetter-Ject®. At the development of Vetter- Ject® particular emphasis was laid on the usability.

Ludwig Cancer Research & University of Oxford Launch Cancer Immunotherapy Spinout
Isis Innovation, the University of Oxford’s technology commercialisation company, and Ludwig Cancer Research are proud to announce the launch of a new spinout company, iOx Therapeutics. iOx Therapeutics will develop a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Professor Vincenzo Cerundolo, the director of the MRC Human Immunology Unit within the University of Oxford’s Weatherall Institute of Molecular Medicine.

Exostar's Identity Hubs - Making Security a Business Enabler Throughout the Drug Development ProcessExostar's Identity Hubs - Making Security a Business Enabler Throughout the Drug Development Process
With a price tag north of $1B and a duration in the neighborhood of a decade, the drug development process costs too much and takes too long. That’s not news. In fact, pharmaceutical companies are in the midst of a sea change to a partner-centric business model to combat the problem.

“Biomaterial of the Future” Nanocellulose to Send Market Booming with 42.8% CAGR
BCC Research reveals in its new report, Cellulose Nanoparticles: Processing, Applications and Global Markets, that because of its outstanding properties, rapidly decreasing manufacturing costs, and a positive toxicological profile, Nanocellulose (NC) is currently being used in nearly unlimited applications and sectors.

Exostar & Taigle Partnership Delivers Solutions to Life Science & Healthcare Markets
Exostar, an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, and Taigle mySignatureBook, a leading digital workflow provider in the life sciences industry, announced a partnership that integrates Taigle’s mySignatureBook (MSB) with Exostar’s Life Sciences Identity Hub.

Global Biosimilars Market Value Could Hit $55 BillionGlobal Biosimilars Market Value Could Hit $55 Billion
The global biosimilars market value is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, with growth primarily driven by a promising pipeline in active development and government efforts to reduce healthcare spending, according to business intelligence provider GBI Research.

Global Gene Therapy Deals Sky-Rocketed to Nearly $5 Billion in 2014Global Gene Therapy Deals Sky-Rocketed to Nearly $5 Billion in 2014
The total number of deals in the global gene therapy market more than doubled from 16 in 2013 to 36 in 2014, with their combined value rising spectacularly from $122.8 million to $4.9 billion over the same period, representing a forty-fold increase, says research and consulting firm GlobalData.

Bristol-Myers Squibb Will Win Big with Melanoma Combination Immunotherapy
Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by Bristol-Myers Squibb (BMS) suggests that its Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape once it is approved, says an analyst with research and consulting firm GlobalData.

SIGNiX & Exostar Partner to Deliver Secure, Compliant Digital Signature Solution to Life Science & HealthcareSIGNiX & Exostar Partner to Deliver Secure, Compliant Digital Signature Solution to Life Science & Healthcare
SIGNiX, the leading provider of Independent E-Signatures, and Exostar, an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, recently announced a relationship that brings SIGNiX’s digital signature solution to Exostar’s life sciences and healthcare communities.

PlasmaTech Announces Name Change to Abeona Therapeutics; Reflects Broader Rare Disease CommitmentPlasmaTech Announces Name Change to Abeona Therapeutics; Reflects Broader Rare Disease Commitment
PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, recently announced a name change to Abeona Therapeutics, Inc. to reflect its broader rare disease commitment.

Emulate Announces Strategic Collaboration With Johnson & Johnson Innovation to Use Organs-on-Chips Platform Emulate Announces Strategic Collaboration With Johnson & Johnson Innovation to Use Organs-on-Chips Platform
Emulate, Inc. recently announced that it recently formed a research collaboration with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson (Janssen), to deploy Emulate’s Organs-on-Chips platform across certain Janssen programs to better predict the potential human response of drug candidates and improve the drug development process.

Pancreatic Cancer Treatment Pipeline Dominated by Early Stage DevelopmentPancreatic Cancer Treatment Pipeline Dominated by Early Stage Development
While the treatment pipeline for pancreatic cancer shows a high level of innovation, with 52% of products categorized as first-in-class, most development is in the early stages, meaning a significant proportion of therapies are unlikely to reach the market in the near future, says business intelligence provider GBI Research.

Ajinomoto Althea Receives European GMP Certification for Commercial Aseptic Filling & Testing Ajinomoto Althea Receives European GMP Certification for Commercial Aseptic Filling & Testing
Ajinomoto Althea, Inc. (Althea), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate from the Health Products Regulatory Authority (HPRA) for commercial aseptic filling and testing.

Trehalose:  A Powerful Excipient in the Formulation ToolboxTrehalose: A Powerful Excipient in the Formulation Toolbox
Trehalose is a non-reducing disaccharide consisting of two glucose molecules linked by an α,α–1,1 glycosidic bond. In the pharmaceutical industry, products that benefit from the stabilizing effects of trehalose include, but are not limited to: monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), fusion proteins, peptides, stem cells, and vaccines.

BIND Therapeutics & Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting PlatformBIND Therapeutics & Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting Platform
BIND Therapeutics, Inc. and Macrophage Therapeutics recently announced they have entered into a research collaboration to engineer Accurins with the Manocept™ targeting platform that enables selective, efficient binding to CD206 positive disease-associated macrophages.

Targeted Therapeutics & NanoparticlesTargeted Therapeutics & Nanoparticles
Formulation technologies are a critical contributor to current and future improvements in pharmaceutical and biopharmaceutical development. Because of their compelling advantages, nanoparticles will see rapidly increasing adoption and use in both pharmaceutical and biopharmaceutical products.

The CDMO Market: Implications of Patheon's IPO
Patheon's announcement this week that it plans to file for an initial public offering (IPO) is the latest move by the company, which has been actively building its capabilities through targeted acquisitions. So what is the impact on the pharma outsourcing market?

SGS Life Science Services Opens New Lab; Broadens Biologics Capabilities
SGS Life Science Services, the leading analytical and bioanalytical contract solutions provider, today announced the planned opening of its new bio/pharmaceutical quality control laboratory at Villeneuve La Garenne, a Paris suburb, replacing an existing facility in Clichy.

Glaucoma Treatment Market Value Will Grow Moderately to $3 Billion
The treatment market for glaucoma will rise in value from $2.4 billion in 2013 to approximately $3 billion by 2023 across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, UK, and Japan, representing a moderate overall Compound Annual Growth Rate (CAGR) of 2.4%, says research and consulting firm GlobalData.

Drug Abuse Triggers Regulations to Push the Development of Tamper-Resistant Opioid Formulations for Pain Management
The pain market is currently dominated by opioid analgesics, which have well-known side effects, such as addiction and constipation. However, a $10-billion market exists for a company able to develop a novel, targeted pain therapy that excludes these side effects, indicating the huge opportunity for growth in this mature industry.

Strategic Product Lifecycle Management Through Secondary Packaging Strategic Product Lifecycle Management Through Secondary Packaging
Developing and launching a new drug is often a burden on resources, time and money. Pharmaceutical and biotech companies can only afford the additional expense if and when a product achieves long-term success. Early implementation of strategic product lifecycle management (PLM) allows to significantly increase their drug's prospects on the markets. Secondary packaging can actually play a decisive role throughout the product's entire lifecycle.

bluebird bio Announces Global Regulatory Strategy for Gene Therapybluebird bio Announces Global Regulatory Strategy for Gene Therapy
bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, recently announced it has met with regulatory authorities in Europe and the United States to discuss potential approval pathways for its LentiGlobin BB305 product candidate for the treatment of beta-thalassemia major.

West Bolsters R&D Strategy With Global Site Expansions & UpgradesWest Bolsters R&D Strategy With Global Site Expansions & Upgrades
West Pharmaceutical Services, Inc. announced a multi-year investment as part of the company’s evolving research and development strategy.

XenoTech Accepting Global Scientific Achievement Award Nominations for 2015 XenoTech Accepting Global Scientific Achievement Award Nominations for 2015
XenoTech, a division of Sekisui, is accepting nominations for the 2015 XenoTech Global Scientific Achievement Award. This award is presented annually in recognition of meritorious, scientific contribution and achievement to further research in the field of ADME/DMPK.

Vcaps® Plus Capsules: A New HPMC Capsule for Optimum Formulation of Pharmaceutical Dosage FormsVcaps® Plus Capsules: A New HPMC Capsule for Optimum Formulation of Pharmaceutical Dosage Forms
HPMC capsules were originally formulated with a secondary gelling agent. This agent can delay dissolution in some circumstances and lead to unwanted issues during product development. In this article, we discuss the rationale for developing Capsugel’s Vcaps® Plus capsules without a gelling agent. We also describe how these capsules – now in use at many major pharmaceutical companies to encapsulate their existing OTC products and NCEs – can optimize product performance and improve product stability, as we...






















- SHL


Click here to see the showcases


INTERPHEX
March 21-23
New York, NY

PDA Annual Meeting
April 3-5
Anaheim, CA

RDD (Respiratory Drug Delivery)
April 25-28
Nice, France

Pre-filled Syringes East Coast
April 26-27
Boston, MA


AAPS National Biotechnology Meeting
May 1-3
San Diego, CA

Innovation Networking Summit & Table-top Exhibition
May 4-5
Hilton Hotel, Parsippany, NJ

CPhI North America & Informex
May 16-18
2017 Philadelphia, PA

BIO 2017
June 19 - 22
San Diego, CA

Controlled Release Society Meeting
July 16-19 Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Nienna, Austria

AAPS
November 12-17
San Diego, CA

 



Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions